|
 US FDA 200+Complete Response Letters (CRLs) of drugs and biological products between 2020 and 2024 released on July 10, 2025 will help pharma industry to engage in a more transparent manner, according to experts.
Experts further explain that this will enhance not just access to information but the quality of decision-making across development teams, regulatory affairs team, and market strategy team of global pharma companies. The US FDA has published 200 plus CRLs in response to applications submitted for approval of drugs or biological products between 2020 and 2024. These letters are no longer just feedback to a company they are learning resources for an entire industry.
CRLs are formal decision letters sent to applicants when the US FDA determines that a new drug application (NDA) or biologics license application (BLA) cannot be approved in its current form, often due to issues such as safety concerns, efficacy data deficiencies, manufacturing problems, or bioequivalence failures.
Until now, CRLs were not public, making it difficult to understand the real reasons behind non-approvals. In fact, a 2015 US FDA analysis found that sponsors omitted 85% of the agency’s concerns when publicly announcing a rejection. This has limited industry learning and perpetuated common mistakes.
A pharma industry expert said, “Global pharma companies CRL isn’t private anymore. The US FDA just flipped the script on how biotech, contract research organization (CRO), and contract development and manufacturing organization (CDMO) marketers need to communicate.”
According to sources, the CRLS which are now public, are not just summaries, but talk about manufacturing lapses, trial design flaws, and safety data gaps. Investors, competitors and litigators can all see exactly why a drug got rejected. It encourages the industry to engage in more transparent, data-driven communication with stakeholders.
On July 10, 2025, the US FDA announced that it had published an initial batch of more than 200 CRLs as part of a new transparency initiative. The US FDA has indicated that additional CRLs will be released in the future as part of this ongoing effort to modernize and enhance transparency in its review processes. The full texts are available via the openFDA platform or Drugs@FDA database for public access.
|